Routine hepatitis C (HCV) antibody testing of men who have sex with men (MSM) at an Amsterdam sexually transmitted infection (STI) clinic yielded additional and earlier HCV diagnoses in HIV-positive men attending an HIV clinic.
A study of state departments of correction concludes that prisoners are not receiving vital hepatitis C treatment due to extremely high drug costs.
U.S. Liver Organization Recommends That People With Hepatitis C Be Tested for Hepatitis B Before Starting Antiviral Therapy
The American Association for the Study of Liver Diseases has issued a statement saying all patients beginning hepatitis C treatment using direct-acting antivirals should be assessed for hepatitis B to avoid potential "mild to severe liver injury that...
Phase 2a results were announced in a study to understand the safety and to determine an effective dose of the combination of odalasvir, AL-335 with and without simeprevir to treat HCV genotype 1 treatment-naive patients.
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
"The Veterans Affairs Healthcare system is a perfect place to test for 'real world' results," Alan Franciscus writes. "How do the direct-acting antiviral drugs work in a 'real world' setting as opposed to clinical trials?"
An important study was recently published in Lancet Gastroenterology & Hepatology holds the promise of changing the way that people with hepatitis C are treated.
Consequences of Inaccurate Hepatitis C Virus Genotyping on the Costs of Prescription of Direct Antiviral Agents in an Italian District
Researchers conducted a study to analyze commercial hepatitis C genotype/subtype assays to understand the cost-effectiveness of potential errors in the assays.
"Not only is nothing private on the internet, it is forever," Lucinda K. Porter, R.N., writes. "Information cannot be erased from the web. So, if you don't want people to know about your having hepatitis C, don't tell anyone."
Type of antiretroviral regimen did not affect sustained virologic response 12 weeks after therapy stopped (SVR12) in a 12-week trial of daclatasvir/sofosbuvir (DCV/SOF).
"Health disparities can act a bit like compound interest," Matthew Zielske writes. "Each new health or socioeconomic concern that arises will be added to the existing pool of problems which will lead to further tangling the knot."